Window Therapeutics is proud to be named an NCL awardee by the @National Cancer Institute’s Nanotechnology Characterization Laboratory. As an NCL awardee, our Antibody Brush-analogue macromolecule Conjugate (ABC) technology will undergo rigorous evaluation, bringing us closer to clinical trials and paving the way for a new era in cancer therapy.
For more information, see the NCL website here (https://www.cancer.gov/nano/research/ncl/about/collaborators)
Nanotechnology Characterization Lab Collaborators
